Manatt Health Partner Rachel Sher was quoted in MedTech Dive on Congress’ September 30 deadline to reauthorize the Food and Drug Administration’s (FDA) user fees programs, which provide funding for the review of prescription drugs, medical devices and other products for the next five years.
According to the article, Congress is discussing attaching the package to a continuing resolution, although it is unclear which specific provisions will be included. “Congressional leaders have indicated that they recognize the importance of reauthorizing FDA’s user fee programs before they expire on September 30,” said Sher. “So there is growing optimism that a 5-year legislative reauthorization will be attached to the continuing resolution. Discussions are ongoing regarding which FDA-related policy riders will also be included.”
Read the full article here.